JP2013532170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013532170A5 JP2013532170A5 JP2013518688A JP2013518688A JP2013532170A5 JP 2013532170 A5 JP2013532170 A5 JP 2013532170A5 JP 2013518688 A JP2013518688 A JP 2013518688A JP 2013518688 A JP2013518688 A JP 2013518688A JP 2013532170 A5 JP2013532170 A5 JP 2013532170A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound according
- compound
- disorder
- chlorophenoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- LZLQEDMHCMNYFK-FZMZJTMJSA-N (3s)-3-[(1s)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine Chemical compound O([C@@H](C(C)C)[C@@H]1CNCC1)C1=CC=C(Cl)C=C1 LZLQEDMHCMNYFK-FZMZJTMJSA-N 0.000 claims description 6
- 208000027520 Somatoform disease Diseases 0.000 claims description 6
- 239000012454 non-polar solvent Substances 0.000 claims description 6
- 208000027753 pain disease Diseases 0.000 claims description 6
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 4
- 208000028698 Cognitive impairment Diseases 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 4
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 4
- 239000003701 inert diluent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000009245 menopause Effects 0.000 claims description 4
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 230000001457 vasomotor Effects 0.000 claims description 4
- 208000017194 Affective disease Diseases 0.000 claims description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000008930 Low Back Pain Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical group COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 2
- 229960002748 norepinephrine Drugs 0.000 claims description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 2
- 239000003402 opiate agonist Substances 0.000 claims description 2
- 239000003401 opiate antagonist Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims description 2
- 229940125794 sodium channel blocker Drugs 0.000 claims description 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- SRMSYUHYMSSVCS-YOEHRIQHSA-N tert-butyl (3s)-3-[(1s)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine-1-carboxylate Chemical compound O([C@@H](C(C)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)C1=CC=C(Cl)C=C1 SRMSYUHYMSSVCS-YOEHRIQHSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36277310P | 2010-07-09 | 2010-07-09 | |
| US61/362,773 | 2010-07-09 | ||
| PCT/US2011/042518 WO2012006205A1 (en) | 2010-07-09 | 2011-06-30 | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015063809A Division JP2015120752A (ja) | 2010-07-09 | 2015-03-26 | ３−フェノキシメチルピロリジン化合物の結晶性形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013532170A JP2013532170A (ja) | 2013-08-15 |
| JP2013532170A5 true JP2013532170A5 (cg-RX-API-DMAC7.html) | 2014-06-19 |
| JP5823512B2 JP5823512B2 (ja) | 2015-11-25 |
Family
ID=44510052
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013518688A Expired - Fee Related JP5823512B2 (ja) | 2010-07-09 | 2011-06-30 | ３−フェノキシメチルピロリジン化合物の結晶性形態 |
| JP2015063809A Withdrawn JP2015120752A (ja) | 2010-07-09 | 2015-03-26 | ３−フェノキシメチルピロリジン化合物の結晶性形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015063809A Withdrawn JP2015120752A (ja) | 2010-07-09 | 2015-03-26 | ３−フェノキシメチルピロリジン化合物の結晶性形態 |
Country Status (20)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102471258A (zh) * | 2009-07-13 | 2012-05-23 | 施万制药 | 3-苯氧基甲基吡咯烷化合物 |
| CN103038211B (zh) * | 2010-07-09 | 2015-04-15 | 施万生物制药研发Ip有限责任公司 | 3-苯氧基甲基吡咯烷化合物的结晶形式 |
| US12369722B2 (en) | 2018-05-23 | 2025-07-29 | L&P Property Management Company | Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate |
| US11013340B2 (en) | 2018-05-23 | 2021-05-25 | L&P Property Management Company | Pocketed spring assembly having dimensionally stabilizing substrate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| ATE324365T1 (de) * | 2000-08-31 | 2006-05-15 | Pfizer | Phenoxyphenylheterozyklen als serotonin- wiederaufnahmehemmer |
| US20070072859A1 (en) * | 2004-03-05 | 2007-03-29 | Eli Lilly And Company | Pharmaceutical compounds |
| US20100120858A1 (en) * | 2006-08-23 | 2010-05-13 | Pfizer Inc. | Piperidine Derivatives |
| WO2008153958A2 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'- (3-methoxy-propane-1- sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| ES2434250T3 (es) * | 2008-07-24 | 2013-12-16 | Theravance, Inc. | Compuestos de 3-(fenoxifenilmetil)pirrolidina |
| US20100267743A1 (en) * | 2009-04-15 | 2010-10-21 | Stangeland Eric L | 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds |
| CN102471258A (zh) * | 2009-07-13 | 2012-05-23 | 施万制药 | 3-苯氧基甲基吡咯烷化合物 |
| CN103038211B (zh) * | 2010-07-09 | 2015-04-15 | 施万生物制药研发Ip有限责任公司 | 3-苯氧基甲基吡咯烷化合物的结晶形式 |
-
2011
- 2011-06-30 CN CN201180033815.4A patent/CN103038211B/zh not_active Expired - Fee Related
- 2011-06-30 KR KR1020137001583A patent/KR20130041916A/ko not_active Withdrawn
- 2011-06-30 US US13/173,204 patent/US8163794B2/en not_active Expired - Fee Related
- 2011-06-30 PH PH1/2013/500051A patent/PH12013500051A1/en unknown
- 2011-06-30 RU RU2013105479/04A patent/RU2013105479A/ru not_active Application Discontinuation
- 2011-06-30 AU AU2011276416A patent/AU2011276416B2/en not_active Ceased
- 2011-06-30 NZ NZ605490A patent/NZ605490A/en not_active IP Right Cessation
- 2011-06-30 BR BR112013000602A patent/BR112013000602A2/pt not_active IP Right Cessation
- 2011-06-30 MX MX2013000334A patent/MX2013000334A/es active IP Right Grant
- 2011-06-30 CA CA2803090A patent/CA2803090A1/en not_active Abandoned
- 2011-06-30 WO PCT/US2011/042518 patent/WO2012006205A1/en not_active Ceased
- 2011-06-30 EP EP11738521.1A patent/EP2590941A1/en not_active Withdrawn
- 2011-06-30 SG SG2012094348A patent/SG186789A1/en unknown
- 2011-06-30 JP JP2013518688A patent/JP5823512B2/ja not_active Expired - Fee Related
- 2011-07-07 AR ARP110102429A patent/AR083512A1/es unknown
- 2011-07-08 TW TW100124302A patent/TW201206882A/zh unknown
-
2012
- 2012-03-20 US US13/424,561 patent/US8383669B2/en not_active Expired - Fee Related
- 2012-12-12 IL IL223584A patent/IL223584A0/en unknown
- 2012-12-19 US US13/720,385 patent/US8791151B2/en not_active Expired - Fee Related
-
2013
- 2013-01-07 ZA ZA2013/00154A patent/ZA201300154B/en unknown
- 2013-01-09 CL CL2013000085A patent/CL2013000085A1/es unknown
- 2013-01-09 CO CO13003305A patent/CO6680604A2/es not_active Application Discontinuation
-
2014
- 2014-06-24 US US14/313,422 patent/US9120746B2/en not_active Expired - Fee Related
-
2015
- 2015-03-26 JP JP2015063809A patent/JP2015120752A/ja not_active Withdrawn